Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Invested Capital (2016 - 2025)

Immucell (ICCC) has disclosed Invested Capital for 16 consecutive years, with $39.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital rose 5.02% year-over-year to $39.3 million, compared with a TTM value of $39.3 million through Sep 2025, up 5.02%, and an annual FY2024 reading of $29.2 million, up 12.5% over the prior year.
  • Invested Capital was $39.3 million for Q3 2025 at Immucell, up from $30.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $39.3 million in Q3 2025 and bottomed at $25.9 million in Q4 2023.
  • Average Invested Capital over 5 years is $33.1 million, with a median of $33.2 million recorded in 2021.
  • The sharpest move saw Invested Capital decreased 17.42% in 2023, then rose 24.72% in 2024.
  • Year by year, Invested Capital stood at $33.4 million in 2021, then fell by 5.9% to $31.4 million in 2022, then decreased by 17.42% to $25.9 million in 2023, then increased by 12.5% to $29.2 million in 2024, then skyrocketed by 34.61% to $39.3 million in 2025.
  • Business Quant data shows Invested Capital for ICCC at $39.3 million in Q3 2025, $30.1 million in Q2 2025, and $39.2 million in Q1 2025.